ORAVIG Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Oravig, and when can generic versions of Oravig launch?
Oravig is a drug marketed by Galt Pharms and is included in one NDA. There are three patents protecting this drug.
This drug has twenty-four patent family members in fourteen countries.
The generic ingredient in ORAVIG is miconazole. There are twenty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the miconazole profile page.
DrugPatentWatch® Generic Entry Outlook for Oravig
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be September 11, 2022. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for ORAVIG
International Patents: | 24 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 103 |
Patent Applications: | 4,012 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ORAVIG |
What excipients (inactive ingredients) are in ORAVIG? | ORAVIG excipients list |
DailyMed Link: | ORAVIG at DailyMed |


DrugPatentWatch® Estimated Generic Entry Opportunity Date for ORAVIG
Generic Entry Date for ORAVIG*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;BUCCAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for ORAVIG
Drug Class | Azole Antifungal |
Anatomical Therapeutic Chemical (ATC) Classes for ORAVIG
US Patents and Regulatory Information for ORAVIG
ORAVIG is protected by three US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ORAVIG is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ORAVIG
Prolonged release bioadhesive therapeutic systems
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF OROPHARYNGEAL CANDIDIASIS
Prolonged release bioadhesive therapeutic systems
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF OROPHARYNGEAL CANDIDIASIS
Prolonged release bioadhesive therapeutic systems
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Galt Pharms | ORAVIG | miconazole | TABLET;BUCCAL | 022404-001 | Apr 16, 2010 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Galt Pharms | ORAVIG | miconazole | TABLET;BUCCAL | 022404-001 | Apr 16, 2010 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Galt Pharms | ORAVIG | miconazole | TABLET;BUCCAL | 022404-001 | Apr 16, 2010 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ORAVIG
See the table below for patents covering ORAVIG around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Israel | 159842 | SUSTAINED-RELEASE THERAPEUTIC BIOADHESIVE SYSTEMS | See Plans and Pricing |
Cyprus | 1107828 | See Plans and Pricing | |
European Patent Office | 1792610 | Systèmes thérapeutiques bioadhésifs à libération prolongée (Sustained release bioadhesive therapeutic systems) | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |